BioSpace News Archive

BioCapital

Processa Pharmaceuticals to Present at the MedInvest Oncology Investor Conference

Processa Pharmaceuticals, Inc. announces that Dr. David Young, President of Research and Development, will present virtually at the MedInvest Oncology Investor Conference.

November 30, 2023
·
3 min read
Biotech Bay

Guardant Health to present data at San Antonio Breast Cancer Symposium demonstrating utility of liquid biopsy in biomarker identification, therapy selection and residual disease detection

Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, will present data showing the utility of liquid biopsy tests in the management of breast cancer patients at the San Antonio Breast Cancer Symposium, December 5-9 in San Antonio, Texas.

November 30, 2023
·
5 min read
Lone Star Bio

CMS Posts Final Payment Determination for bioAffinity Technologies’ CyPath® Lung Effective January 2024

bioAffinity Technologies, Inc. announced that the Centers for Medicare and Medicaid Services has made a final determination for payment for CyPath® Lung, a noninvasive test for early-stage lung cancer, for the 2024 calendar year.

November 30, 2023
·
5 min read
Business

KromaTiD and SeQure Dx enter partnership agreement to offer comprehensive, IND-enabling gene editing services supporting cell and gene therapy research

KromaTiD and SeQure Dx announced today a partnership to market a comprehensive and integrated analysis of off-target gene editing in support of cell and gene therapy research, Investigational New Drug (IND) applications and drug product development.

November 30, 2023
·
4 min read
Drug Development

Inipharm Initiates Dosing in Phase 1 Study of Its Small Molecule Inhibitor of HSD17B13

Inipharm today announced that it has begun dosing in a Phase 1 study of INI-822, its orally-delivered small molecule inhibitor of HSD17B13.

November 30, 2023
·
3 min read
FDA

Edgewise Receives Orphan Drug and Rare Pediatric Disease Designations for Its Muscular Dystrophy Program from FDA

Edgewise Therapeutics, Inc. today announced that the U.S. Food & Drug Administration (FDA) has granted EDG-5506 Orphan Drug Designation (ODD) for the treatment of Duchenne muscular dystrophy (Duchenne) and Becker muscular dystrophy (Becker) and Rare Pediatric Disease Designation (RPDD) for the treatment of Duchenne.

November 30, 2023
·
8 min read
Business

Bayer and CrossBay Medical to develop novel Intrauterine System Inserter

Bayer and CrossBay Medical Inc., today announced a development and option to license agreement that will allow the development and production of a single-handed inserter to be combined with Bayer’s leading hormonal IUS portfolio.

November 30, 2023
·
4 min read
Genetown

Alnylam Ranks #1 on Boston Globe’s Top Places to Work List for 2023

Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced its first-place ranking in Boston Globe’s 2023 Top Places to Work in the “Largest Employer” category.

November 30, 2023
·
3 min read
BioMidwest

Dyadic Attends Investor Events in December 2023

Dyadic International, Inc. announced that its management will be attending the following investor events during the month of December:

November 30, 2023
·
3 min read
Zymeworks Announces Participation in Upcoming Investor Conference - November 30, 2023

Zymeworks Inc. today announced that management will participate in an upcoming investor conference.

November 30, 2023
·
2 min read